Drug Target Review

Engineering the next generation of T-cell engagers

Explore the evolution of T-cell engagers, from experimental concepts to effective therapies for haematologic malignancies.

Beth Israel doctors on high cancer remission rates that show the potential of CAR T cell therapy

Doctors at Boston’s Beth Israel share how CAR T cell therapy and other emerging immune therapies are delivering promising ...
European Medical Journal

Personalised T Cell Activator Shows Promise

A phase one study shows personalised T cell activation induced durable immune responses with manageable toxicity in patients with chronic lymphocytic leukaemia receiving targeted therapy.
The Week

Can IIT Bombay’s safer T-Cell retrieval make CAR T-Cell therapy more accessible?

CAR T-cell therapy, considered one of the most promising breakthroughs in cancer treatment, works by harnessing the patient’s ...
Targeted Oncology

NPX372, Novel T-Cell Engager in Solid Tumors, Gains IND Clearance

The FDA has cleared the investigational new drug (IND) application for NPX372, a first-in-class T-cell engager (TCE) for the ...
The Manila Times

Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma

PiNACLE - H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of ...
News-Medical.Net on MSN

Alzheimer’s plaques decline after CAR-T immune cell treatment in preclinical study

By Hugo Francisco de Souza A novel CAR-T cell approach targets amyloid plaques in preclinical Alzheimer models, raising the ...
Technology Networks

CAR T Therapy Reduces Amyloid Plaques in Alzheimer’s Model

Researchers used CAR T therapy to target beta amyloid plaques in Alzheimer’s disease. In mice, the modified immune cells ...